Unveiling Adult Polycystic Kidney Disease: Historical Perspectives and Evidence-Based Management Approaches
Year: 2024
Type: article
Abstract: Background: Adult polycystic kidney disease is an important contributor to chronic renal failure, marked by a highly variable clinical trajectory and progression to chronic renal failure. Diagnosis typically relies on ultrasound imaging, with genetic testing being less commonly necessary. Management strategies aim to delay the onset of chronic renal failure or slow its progression, involving interventions such as antihypertensive medications, dietary protein restriction, and prompt treatment of urinary tract infections. This paper aims to present the case of an Iraqi patient diagnosed early, prior to the onset of renal failure, and to outline evidence-based treatment options. Patients and methods: A thirty-year-old female with recurrent urinary tract infections sought evaluation following her uncle's recent diagnosis of chronic renal failure due to adult polycystic kidney disease. Her uncle had developed progressive symptomatic uremia at age 52, accompanied by gradual hearing loss, a rare association with this condition. Her aunt had succumbed to chronic renal failure. Results: The patient exhibited normotension and renal function tests revealed normal values. A renal ultrasound depicted normal-sized kidneys with multiple cysts observed bilaterally, with the largest measuring 3 centimeters, confirming the diagnosis of adult polycystic kidney disease. Conclusion and expert opinion: This article delves into the realm of adult polycystic kidney disease, offering insights into its historical context, diagnostic methods, and evidence-based management strategies. Beginning with the earliest recorded case in history, the narrative progresses through key milestones in understanding the disease, emphasizing diagnostic techniques such as ultrasound imaging. The current evidence-based expert opinion suggests that the long-term use simvastatin plus octreotide-long-acting release monthly injection in patients with adult polycystic kidney disease to slow the growth of cysts and the deterioration in renal function. The use of tolvaptan can also be considered, but it is associated increased adverse effects such as thirst, polyuria, and hepatic injury.
Author: Aamir Jalal Al-Mosawi
Institution: Baghdad Medical City
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4407174516